MET
Universal Cellular Machinery · Phosphorylation & Kinase Signaling Cascades
What signal does the MET receptor receive?
MET encodes the receptor for hepatocyte growth factor. Activating it relays growth and tissue-response signals, with cancer-treatment implications limited to appropriate clinical and molecular contexts.
- Common Gene Name
- MET proto-oncogene, receptor tyrosine kinase
- NCBI Gene ID
- 4233
- Chromosome
- 7
Clinical Evidence Status
Actionability report availableEstablished disease relationshipTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (7 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| papillary renal cell carcinoma | ClinGen gene-disease validity | Definitive | Autosomal dominant | View source 2018-10-11 |
| complex neurodevelopmental disorder | ClinGen gene-disease validity | Disputed | Autosomal dominant | View source 2021-01-19 |
| nonsyndromic genetic hearing loss | ClinGen gene-disease validity | Limited | Autosomal recessive | View source 2021-03-26 |
| Familial papillary renal cell carcinoma 1 | ClinGen clinical actionability | Scored report; not a validity grade | Adult | View source 2022-02-09 |
| Capmatinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Tepotinib (3) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Telisotuzumab Vedotin-tllv (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Universal Cellular Machinery